MARKET

RNA

RNA

Atrium Therapeutics, Inc
NASDAQ
13.30
+0.16
+1.22%
Pre Market: 13.35 +0.05 +0.38% 07:23 05/14 EDT
OPEN
13.11
PREV CLOSE
13.14
HIGH
13.30
LOW
12.91
VOLUME
259
TURNOVER
--
52 WEEK HIGH
16.77
52 WEEK LOW
11.95
MARKET CAP
227.62M
P/E (TTM)
-4.5983
1D
5D
1M
3M
1Y
5Y
1D
Trump Trade: U.S. plans AI security order without required model tests
TipRanks · 2d ago
Trump approves plan to fire FDA head Marty Makary, CBS reports
TipRanks · 2d ago
Weekly Report: what happened at RNA last week (0504-0508)?
Weekly Report · 3d ago
Trump plans to fire FDA commissioner Marty Makary, WSJ reports
TipRanks · 5d ago
Weekly Report: what happened at RNA last week (0427-0501)?
Weekly Report · 05/04 10:43
HC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics
Benzinga · 05/01 11:11
Weekly Report: what happened at RNA last week (0420-0424)?
Weekly Report · 04/27 10:48
BUZZ-U.S. STOCKS ON THE MOVE- Lululemon, United Rentals, cannabis stocks
Reuters · 04/23 17:44
More
About RNA
Atrium Therapeutics, Inc. is a biopharmaceutical company engaged in the delivery of ribonucleic acid (RNA) therapeutics for people living with cardiomyopathy. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. It is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.

Webull offers Atrium Therapeutics Inc stock information, including NASDAQ: RNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNA stock methods without spending real money on the virtual paper trading platform.